TransCode Therapeutics公司近日向美国证券交易委员会提交文件,披露部分持股股东计划转售该公司普通股,总量最高可达约1600万股。此次转售申请涉及二级市场交易,现有股东拟通过公开市场减持所持股份。
TransCode Therapeutics公司近日向美国证券交易委员会提交文件,披露部分持股股东计划转售该公司普通股,总量最高可达约1600万股。此次转售申请涉及二级市场交易,现有股东拟通过公开市场减持所持股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.